Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis

Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade of CD25 inhibits effector T cell activation, regulatory T cell expansion and survival, and activation-induced T-cell apoptosis. Because CD25...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohan, Stanley L., Lucassen, Elisabeth B., Romba, Meghan C., Linch, Stefanie N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480729/
https://www.ncbi.nlm.nih.gov/pubmed/30862055
http://dx.doi.org/10.3390/biomedicines7010018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480729/
https://www.ncbi.nlm.nih.gov/pubmed/30862055
http://dx.doi.org/10.3390/biomedicines7010018

Ejemplares similares